| Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal TJ Mitchell, S Turajlic, A Rowan, D Nicol, JHR Farmery, T O’Brien, ... Cell 173 (3), 611-623. e17, 2018 | 475 | 2018 |
| Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer M Meylan, F Petitprez, E Becht, A Bougoüin, G Pupier, A Calvez, I Giglioli, ... Immunity 55 (3), 527-541. e5, 2022 | 275 | 2022 |
| Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting B Beuselinck, S Job, E Becht, A Karadimou, V Verkarre, G Couchy, ... Clinical cancer research 21 (6), 1329-1339, 2015 | 272 | 2015 |
| Multicentre randomised phase II trial of gemcitabine+ platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2 S Oudard, S Culine, Y Vano, F Goldwasser, C Théodore, T Nguyen, ... European journal of cancer 51 (1), 45-54, 2015 | 155 | 2015 |
| Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib B Beuselinck, S Oudard, O Rixe, P Wolter, A Blesius, J Ayllon, R Elaidi, ... Annals of oncology 22 (4), 794-800, 2011 | 153 | 2011 |
| Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases B Beuselinck, P Wolter, A Karadimou, R Elaidi, H Dumez, A Rogiers, ... British Journal of Cancer 107 (10), 1665-1671, 2012 | 140 | 2012 |
| Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open … YA Vano, R Elaidi, M Bennamoun, C Chevreau, D Borchiellini, D Pannier, ... The Lancet Oncology 23 (5), 612-624, 2022 | 89 | 2022 |
| Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients YA Vano, S Oudard, MA By, P Tetu, C Thibault, H Aboudagga, F Scotté, ... PloS one 13 (4), e0195042, 2018 | 78 | 2018 |
| VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib–a multicentric retrospective analysis B Beuselinck, A Karadimou, D Lambrechts, B Claes, P Wolter, G Couchy, ... Acta oncologica 53 (1), 103-112, 2014 | 69 | 2014 |
| Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit S Oudard, RT Elaidi Cancer treatment reviews 38 (8), 981-987, 2012 | 69 | 2012 |
| Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer A Angelergues, D Maillet, A Fléchon, M Ozgüroglu, F Mercier, A Guillot, ... European journal of cancer 50 (9), 1602-1609, 2014 | 67 | 2014 |
| Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma S Oudard, J Medioni, J Aylllon, E Barrascourt, RT Elaidi, J Balcaceres, ... Expert review of anticancer therapy 9 (6), 705-717, 2009 | 63 | 2009 |
| Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated … A Simonaggio, R Elaidi, L Fournier, E Fabre, V Ferrari, D Borchiellini, ... Cancer Immunology, Immunotherapy 69, 2513-2522, 2020 | 51 | 2020 |
| A practical approach to improve safety and management in chemotherapy units based on the PROCHE–Programme for optimisation of the chemotherapy network monitoring program F Scotté, S Oudard, H Aboudagga, R Elaidi, B Bonan European Journal of Cancer 49 (3), 541-544, 2013 | 47 | 2013 |
| Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients J Medioni, G Deplanque, JM Ferrero, T Maurina, JMP Rodier, E Raymond, ... Clinical Cancer Research 20 (17), 4471-4477, 2014 | 46 | 2014 |
| Clear-cell renal cell carcinoma: molecular characterization of IMDC risk groups and sarcomatoid tumors A Verbiest, I Renders, S Caruso, G Couchy, S Job, A Laenen, V Verkarre, ... Clinical genitourinary cancer 17 (5), e981-e994, 2019 | 40 | 2019 |
| Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review WK Oh, D McDermott, C Porta, A Levy, R Elaidi, F Scotte, R Hawkins, ... International journal of oncology 44 (1), 5-16, 2014 | 39 | 2014 |
| BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer N Epaillard, A Simonaggio, R Elaidi, F Azzouz, E Braychenko, C Thibault, ... Bulletin du Cancer 107 (5), eS22-eS27, 2020 | 37 | 2020 |
| Effect of adding docetaxel to androgen-deprivation therapy in patients with high-risk prostate cancer with rising prostate-specific antigen levels after primary local therapy … S Oudard, I Latorzeff, A Caty, L Miglianico, E Sevin, AC Hardy-Bessard, ... JAMA oncology 5 (5), 623-632, 2019 | 35 | 2019 |
| LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC … Y Vano, RT Elaidi, M Bennamoun, CM Chevreau, D Borchiellini, ... Annals of Oncology 31, S1157, 2020 | 34 | 2020 |
